C O M M U N I T Y

Board of Directors
___________________________________

President
Jonathan B. Goode

Vice President
M i c h a e l W. M c G u i l l , D V M , M P H

Tr e a s u r e r
Ronald E. Akie

Clerk
Paul A. Ross, EdD

L y n n M . D e i t z e r, E s q
John Devlin, PharmD
Bernard Dreiblatt
Jeremy Holman, PhD
Rosa L. Hunter
Charlotte A. Kreutzer
Timothy S. Martinez, DMD
R E S E A R C H
of New England
I N I T I A T I V E

Community Research Initiative of New England (CRI)

is an independent, nonprofit community-based organization
dedicated to HIV clinical research, treatment education and
financial assistance for approved drug treatments and health
insurance coverage.

Working to improve the lives of people living with HIV/AIDS

since 1989, Boston-based CRI (led by Dr. Calvin Cohen,
Director of Research) has participated in and initiated some of
the most promising HIV medication research being conducted
in the world. Through its continued outreach efforts, CRI
provides the latest critical treatment information to all people
living with HIV/AIDS, including women, people of color, men
who have sex with men and others who have been traditionally
underserved. CRI also manages the Massachusetts HIV Drug
Assistance Program (HDAP) which ensures access to HIV/AIDS
drugs and health insurance coverage to over 4,000
CRI
L E A D I N G T H E W A Y I N A I D S R E S E A R C H

Lisa Pintchman of those most in need in the state.

Frank A. Ribaudo

NEW
Ricardo H. Rodriguez CRI has produced important research and drug testing data that
A n n We b s t e r, P h D have contributed to the FDA approval of nearly all the currently
___________________________________ available HIV treatments. What CRI discovers from the advanced
clinical research that it conducts has the potential to help people
Executive Director
all over the world who are living with HIV.
Julie K. Marston, MPH

Deputy Executive Director/HDAP Director

C r a i g We l l s , M S L

Director of Research
Calvin J. Cohen, MD, MSc

Associate Director of Research - Boston

Amy Colson, MD, MPH

A s s o c i a t e D i r e c t o r o f R e s e a r c h – We s t
Daniel J. Skiest, MD

C O M M U N I T Y
R E S E A R C H I N I T I A T I V E
of New England

CRI BOSTON
23 MINER STREET • BOSTON, MA 02215 - 3319
TEL: 617-778-5454 FAX ADMINISTRATION/HDAP: 617-778-5455
FAX RESEARCH: 617-778-5456 TOLL FREE: 888-253-2712 TTY: 617-778-5460
C O M M U N I T Y R E S E A R C H I N I T I A T I V E
CRI WEST
7 80 C H E S T N U T S T R E E T • S U I T E 31 • S P R I N G F I E L D , M A 01 10 7 - 1 6 0 0
of New England
TEL : 413-734-2264 FAX: 413-734-2275 TOLL FREE: 888-469-6577

EMAIL : info@crine.org w w w. c r i n e . o r g

HDAP
TEL : 800-228-2714
 CRI dedicates the telling
of our story to the
courageous trial
participants who inspire us,
to our remarkable staff,
volunteers and friends
who challenge us
everyday to find better,
safer treatments and to
our generous supporters
who enable us to continue
our important work.
D E D I C AT I O N
We are especially grateful
to the creative team who
so generously donated their
time, talent and services
to make this publication
possible:
Dickinson Associates
design concept & production
Lucy Cobos Photography
photography
Libretto
writing
Acme Printing Company
printing
In the past 25 years, more than half
a million people have died of
AIDS-related conditions in the US, and
25 million have died worldwide.
Thanks to advances in treatment, the
next quarter-century looks to be more
hopeful. But the point is clear: our
work is not done.
B e t t e r Tr e a t m e n t s . B e t t e r L i v e s .
COMMITMENT
Since 1989, CRI has been working to find treatments for HIV that can
minimize the severity of its impact. There have been many successes. What
once was a death sentence is now a lifelong course of treatment. But while
we have made significant progress, we can never be satisfied so long as a
cure remains elusive.
• CRI’s work encompasses three critical areas:
• We conduct our own investigator-led trials to explore unanswered questions and test innovative ideas.
• We collaborate with pharmaceutical companies in testing their new discoveries.
• We provide access to experimental drugs for those whose current treatments aren’t effective and to
approved drugs for those who can’t afford them.
• No disease in modern history has had the sociopolitical impact of AIDS.
We work closely with committed physicians and courageous patients – and with
the help of generous donors and compassionate friends – we are prepared to
continue our work until it is no longer needed.
1
W h e n C R I w a s f o u n d e d i n 19 8 9 , t h e r e w a s o n l y o n e H I V m e d i c a t i o n a v a i l a b l e . To d ay, t h r o u g h C R I ’ s s i g n i f i c a n t c o n t r i b u t i o n s
to clinical research, there are more than 25 FDA -approved treatments.
“Despite all our successes,
there is no cure for AIDS,
no vaccine – nor is there
likely to be one in our
lifetime. Yet because of
our successes, we have
been able to give patients
more years, more options,
and more hope. We are
L O C A L I M P R I N T. G L O B A L I M PA C T.
working on ways to gain
RESEARCH the ability to quickly
identify the right regimen
for specific patients and
to make it easier for them
to adhere to it. The reality
is that, as far as we’ve
come, there’s still further
to go. And we plan to
stay on this journey
until our work is no
longer necessary.”
“Cal Cohen, MD, MSc
Director of Research
Conducting the highest quality clinical
HIV/AIDS research is one of the
organization’s core activities, and it
has a broad and profound impact on
the lives of people living with HIV and
AIDS. The very process of finding
extraordinary answers to very difficult
questions generates enormous hope.
Though CRI is a small organization – only 35 full-time
staff – its reach is global. From grassroots beginnings in
the late 1980s, CRI today has an international
reputation earned by the quality of its research. Under
the leadership of Dr. Cal Cohen, a world-renowned
researcher, respected physician, and sought-after
presenter at international conferences, CRI has been
involved in testing most of the HIV/AIDS drugs that
have been approved by the FDA to date.
A recent CRI study underscores the importance of our
innovative research. The FOTO pilot study (Five days
of New England
On, Two days Off) examined the efficacy of short-cycle
treatment interruptions. Could participants halt their
regimens on weekends and still keep the virus
suppressed? In asking this question, our goal was to
N I T I A T I V E
improve the quality of life of people on HIV medications
while minimizing side effects and reducing cost. Initial
results were so promising that FOTO is being expanded
to several sites along the eastern seaboard.
I E S E A R C H
Thanks to CRI, many people who are newly diagnosed
with HIV/AIDS can look forward to leading a healthy
life. While that’s a huge improvement over the past, the
R O M M U N I T Y
future will be focused on not only keeping people alive,
but on making those lives fuller and more active.
C
 F o r a s m a n y a s o n e - t h i r d o f t h o s e l i v i n g w i t h H I V, c u r r e n t t r e a t m e n t o p t i o n s a r e n o l o n g e r e f f e c t i v e o r t o l e r a b l e .
CRI is the only research organization in Massachusetts that offers every HIV-related Expanded Access clinical trial.

When researchers complete trials on a “Back in the early 1980s,

new drug, they submit data to the Food when the HIV/AIDS

& Drug Administration (FDA). Even pandemic started, I was

with the most promising drugs, there is an ICU nurse, and I

often a delay before the drug is became used to seeing

approved and available on pharmacy many, many people die of

shelves. This process has always been AIDS-related illnesses

acceptable. Until AIDS. each week. Doing the kind

of clinical research that

E L I M I N A T I N G T H E W A I T .
we do at CRI is so much

Then it became clear that people simply couldn’t wait more hopeful. Even though
for such a time-consuming process. Expanded Access or
there are still way too
Compassionate Use trials were created to provide

pre-market medications to patients for whom current

treatments either were not working or caused

many deaths, people on
COMPASSION
average are living much
intolerable side effects. Unfortunately, estimates

indicate that as many as one-third of all HIV/AIDS longer and in better

patients fit this profile.
health. For some diseases,

These Compassionate Use trials require extensive you may only see one or
regulatory oversight and are usually unfunded. Yet these
of New England

two drugs approved during

studies can yield valuable data and can provide a lifeline

to individuals in need. CRI remains one of the few sites your career. I think we’re
dedicated to offering this type of trial.
very lucky to have so many
N I T I A T I V E

CRI is well suited to conducting this research, since in

good drugs available for
almost every instance we have been involved in earlier

or ongoing trials on the same drugs. Because CRI’s the disease of our lifetime.
mission is not only to research HIV/AIDS drugs but also
I

It’s a gift, really. I feel

E S E A R C H

to provide access to them, Expanded Access trials reflect

our commitment to compassionate treatment and care. incredibly fortunate to be

part of this.”
R O M M U N I T Y

“Lenore Jackson-Pope BSN, ACRN

“Director of Research
Strategy & Development

4
C
 Western Massachusetts has one of the highest rates of HIV infection in the state. CRI Springfield is the only nonprofit organization in the area
dedicated to HIV clinical research. More than 50% of CRI’s clinical trial par ticipants in western Massachusetts are women or people of color.

CRI West was established in 1999 in “There’s a woman who has

response to the high prevalence of HIV been a long-term participant

in Springfield, Massachusetts, and the in CRI drug trials. She is

surrounding communities. Nearly a multi-drug resistant so we

decade later, the Springfield site still have had to stop the trials

offers some of the only adult HIV she was in and then wait

clinical trials in the region. for the drugs to leave her

system before starting the

C O M M U N I T I E S I N N E E D .
next one. And you look at

Though only 90 miles from Boston, Springfield has a her face and see the fear
very different demographic profile. In general, the
and the weariness. I gave
Springfield area is poorer than Boston and is home to a

large Latino community. There are language barriers, her a hug and said, ‘We’re
higher rates of IV drug use, and cultural stigmas to
doing the best we can for
overcome.
you, and we’re hoping the
CRI’s staff, including the bilingual Springfield team, are
attuned to cultural differences and have earned the trust next thing is going to

of the people we enroll in clinical trials. CRI also work.’ And that’s what CRI
addresses the unique needs of the diverse populations
is about: finding that next
served by our two offices. For example, in response to
of New England

the high rates of HIV and Hepatitis B in western thing that will work and
Massachusetts, the Springfield site is host to a Hepatitis
give someone a better
B co-infection study. Now, as ever, CRI works actively to

meet changing community needs. quality of life.”

N I T I A T I V E

“Frances Santiago, RN
Research Coordinator
CRI West
I E S E A R C H

DIVERSITY
R O M M U N I T Y

6
C
 H D A P, s u c c e s s f u l l y m a n a g e d b y C R I s i n c e 1 9 8 9 , p r o v i d e s s e r v i c e s t o m o r e t h a n 4 , 0 0 0 u n i n s u r e d a n d u n d e r i n s u r e d
HIV-positive individuals in need. More t han half of all HDAP enrollees are from communities of color.

Since 1990, CRI has managed the “HIV medications are so

Massachusetts HIV Drug Assistance expensive, and you often

Program (HDAP) on behalf of the don’t take just one. You

Commonwealth of Massachusetts. may take many every

Through HDAP, CRI is able to provide single day for the rest of

HIV-related drugs to more than 4,000 your life. Without HDAP,

Massachusetts residents living with many poor people would

HIV who are in need. die. It’s as simple as that.

More than half of HDAP

R E M O V I N G B A R R I E R S T O T R E A T M E N T.
enrollees are people of

HDAP is among the nation’s most complete drug color, and three-quarters
assistance programs for people living with HIV. The
have incomes of less than
program can pay for medications and drug

co-payments, HIV resistance testing and post-exposure 200% of the federal

prophylaxis (PEP) for potential exposures to HIV.
poverty level. I am proud
ACCESS
Through the Comprehensive Health Insurance

Initiative (CHII), which CRI also administers, HDAP that CRI is involved not
helps to pay insurance premiums and prescription
only in researching new
co-payments for residents who cannot afford them.
drugs for this disease,
Working in partnership with the Massachusetts
of New England

but also helping to make

Department of Public Health, CRI is able to fulfill an

important part of our mission: to ensure access to them available to people

life-saving drugs to those in need. HDAP acts as a payer
in need. I’ve been doing
of last resort, serving people who might otherwise lack
N I T I A T I V E

access to vital care and treatment. Most clients have this for eight years, and
limited incomes. Many are ineligible for other insurance
we are like a family now.”
or entitlement programs. More than half are people of color.
I

“Paco Quiñones
E S E A R C H

With a steady rate of new HIV infections and rising HDAP Clients & Clinical
healthcare costs, efficient management of this complex Vendors Coordinator
program is crucial. HDAP breaks down barriers to
R

treatment so that Massachusetts residents can lead

O M M U N I T Y

healthy and productive lives.

8
C
In the US, African Americans and Hispanics accounted for 82% of all AIDS diagnoses among women in 2005.
“There is still a lot of
misinformation out there.
Kids believe you can get
AIDS from hugging or from
drinking out of someone
else’s glass. They don’t
use condoms, and they
don’t get tested. They
STRAIGHT
could already be infected,
and they don’t know it.
I also hear people say
COMMUNITY that the disease is over
because people are living
longer with it, but that’s
just not true. It’s very
much alive, unfortunately,
and if people want to stay
alive they need access to
this information. We have
to get more serious about
it and make sure young
people know the truth.”
“Laverne Halfkenny
Community Advisory
Board member
CRI’s name begins with “Community”
because it was clear at the very start of
the AIDS crisis that no one could beat
this disease alone – and no one with
this disease deserved to be alone. Only
together can we make a difference in
people’s lives.
TALK AND S U P P O R T.
An ongoing goal of CRI is to bring our mission and all
that we have learned to the community at large. CRI
delivers the message that treatment works. Locally,
regionally, and internationally, we share research results
and treatment education with clinicians, community
members, caregivers, and others affected by HIV.
CRI’s Community Advisory Board (CAB) is an active,
diverse, and experienced group of individuals who go
out and speak to people of all ages and backgrounds
about research, treatment, and the HIV Drug Assistance
Program. Most important, they listen to what people
of New England
say, while compassionately providing the information
often unavailable at school, church, or home.
N I T I A T I V E
I
E S E A R C H
R O M M U N I T Y
11
C
 C R I c o n t i n u e s t o e x p l o r e n ew d r u g r e g i m e n s b e c a u s e l o n g - t e r m a n t i r e t r ov i r a l t r e a t m e n t c a n l e a d t o r e s i s t a n c e t o s o m e o f t h e e x i s t i n g
m e d i c a t i o n s . C R I h a s c o n d u c t e d m o r e t h a n 3 0 0 c l i n i c a l H I V t r i a l s t o c o n t i n u a l ly p r ov i d e s a fe r a n d m o r e e f fe c t i ve t r e a t m e n t o p t i o n s .

Trial participants are not merely “Participating in clinical

specimens in a test tube, they are people trials is a responsibility

with life-threatening illnesses looking that I take very seriously.

for help. And their participation is Having AIDS, I can’t just

anything but passive. Trial participants sit on the sidelines waiting

are courageous people helping to identify for anyone to hand me

effective treatments for themselves and treatment. I need to be an

for others with HIV and AIDS. active participant in

assisting drug companies,

P U T T I N G O N E S E L F O N T R I A L .
my doctors, healthcare

While the focus of our research may be exploring a new providers, and clinical
COURAGE
drug or a combination of medications, the object of our
research centers like CRI.
work is fully human. We do this work because of the

people who might benefit and with the help of the Without people like me,
people who sign up for our studies.
they can’t assess and
Trial recruitment is a critical component of our work.
develop the right treat-
We have to find the most diverse group of willing
participants who understand what is expected of them ments, so for me it’s more

and have the ability to comply with the parameters of of a duty than a choice.
each study for its full duration. What is heartening is
of New England

Information gained
how many people value their participation in our

clinical trials, no matter how ill they may feel or how through my participation
inconvenient it may be.
drives the scientific data
N I T I A T I V E

Drug developers consider it a victory when medications

that ultimately will lead to
succeed in trials. Researchers get credit when successful

study results are presented. Yet the true heroes in our better and more effective
clinical trials are the participants themselves, the
I

treatments for all.”

E S E A R C H

patients who give their time and energy in the hope

that better treatments may be available to all. Their “Stephen

Trial participant
courage inspires us.
R O M M U N I T Y

12
C
C O M M U N I T Y R E S E A R C H I N I T I A T I V E C O M M U N I T Y R E S E A R C H I N I T I A T I V E
of New England of New England

Dear Friends of CRI:

Board of Directors Community Research Initiative of New England (CRI) This has been a year of success and progress, in spite of daunting challenges.* The exciting news is that CRI has
___________________________________ is an independent, nonprofit community-based organization participated in studying several new, powerful treatments now in the final stages of research. These new drugs
show incredible promise. Two of the drugs, expected to be approved soon, are from entirely new drug classes; the
dedicated to HIV clinical research, treatment education and
President third is groundbreaking because it works despite viral resistance to other drugs in its class.
Jonathan B. Goode financial assistance for approved drug treatments and health
insurance coverage. Why do these new drugs matter? Since the beginning of this pandemic, generally only one new drug at a time has
Vice President
been made available, and then only those from existing classes of drugs – to which some people may already have
M i c h a e l W. M c G u i l l , D V M , M P H
Working to improve the lives of people living with HIV/AIDS resistance. Now, for the first time, HIV-positive individuals will be able to start two new drugs at once, should they
Tr e a s u r e r since 1989, Boston-based CRI (led by Dr. Calvin Cohen, need them. And, those medications are from new classes, meaning that they fight the virus in brand new ways.
Ronald E. Akie Director of Research) has participated in and initiated some of
CRI is the only site in the region offering access to clinical trials of all three new antiretrovirals. We provide this
the most promising HIV medication research being conducted
Clerk access despite significant cutbacks of federal dollars supporting community-based research.
Paul A. Ross, EdD in the world. Through its continued outreach efforts, CRI
provides the latest critical treatment information to all people CRI has also successfully operated the HIV Drug Assistance Program (HDAP) this past year despite federal funding
L y n n M . D e i t z e r, E s q challenges. This program, managed in partnership with the state Department of Public Health (DPH) since 1989,
living with HIV/AIDS, including women, people of color, men
John Devlin, PharmD acts as a safety net providing people in need with access to HIV-related medications and health insurance
Bernard Dreiblatt who have sex with men and others who have been traditionally
coverage. CRI was again selected by DPH to manage this complex program for the next five-year cycle. HDAP
Jeremy Holman, PhD underserved. CRI also manages the Massachusetts HIV Drug
served over 4,000 clients in need during 2006 alone, at a time when similar programs in other regions of the
Rosa L. Hunter Assistance Program (HDAP) which ensures access to HIV/AIDS country had to cut services and restrict access. In fact, HDAP has been recognized as a national model for its strong
Charlotte A. Kreutzer
drugs and health insurance coverage to over 4,000 focus on comprehensive health coverage and cost effective management.
Timothy S. Martinez, DMD
Lisa Pintchman of those most in need in the state.
Frank A. Ribaudo This year also marks the completion of a visionary five-year strategic plan by our Board of Directors, with the help
Ricardo H. Rodriguez CRI has produced important research and drug testing data that of our staff, our Community Advisory Board, funders, and other interested stakeholders. The strategic plan renews
A n n We b s t e r, P h D our commitment to conduct HIV-related clinical research of the highest quality – until there is no longer a need.
have contributed to the FDA approval of nearly all the currently
The plan also helps identify ways to diversify our resources and funding base, with the goal of strengthening CRI
___________________________________ available HIV treatments. What CRI discovers from the advanced
in order to meet our future challenges.
clinical research that it conducts has the potential to help people
Executive Director
all over the world who are living with HIV. While CRI’s primary research teams are in Massachusetts, the critical work we do resonates nationally and makes
Julie K. Marston, MPH
an impact globally. In order to rapidly complete CRI investigator-led studies, we have recently expanded to sites
Deputy Executive Director/HDAP Director throughout the country. After careful review and with rigorous quality assurance, we are actively partnering with
C r a i g We l l s , M S L other experienced, community-based research sites in Connecticut, New York, Washington DC, Florida, and California.

Director of Research Most important, we are pleased to report that through the generous support of our loyal donors, along with the
Calvin J. Cohen, MD, MSc commitment of staff and the oversight of our Board of Directors, CRI remains a strong and viable organization.
There is still much work to be done. We are resolute in our goal of finding effective treatments that will promote
Associate Director of Research - Boston
longevity, enhance quality of life, and ensure that those in need have access to the best care and treatment available.
Amy Colson, MD, MPH

A s s o c i a t e D i r e c t o r o f R e s e a r c h – We s t We thank all of you who have done so much to support our work, and we ask for your ongoing help as we
Daniel J. Skiest, MD continue leading the way in AIDS research.

C O M M U N I T Y
R E S E A R C H I N I T I A T I V E
of New England

CRI BOSTON
23 MINER STREET • BOSTON, MA 02215 - 3319
TEL: 617-778-5454 FAX ADMINISTRATION/HDAP: 617-778-5455
FAX RESEARCH: 617-778-5456 TOLL FREE: 888-253-2712 TTY: 617-778-5460

CRI WEST
7 80 C H E S T N U T S T R E E T • S U I T E 31 • S P R I N G F I E L D , M A 01 10 7 - 1 6 0 0
TEL: 413-734-2264 FAX: 413-734-2275 TOLL FREE: 888-469-6577

EMAIL : info@crine.org w w w. c r i n e . o r g Julie Marston Dr. Cal Cohen Craig Wells Jonathan Goode
Executive Director Director of Research Deputy Executive President,
HDAP
TEL : 800-228-2714 Director/HDAP Director Board of Directors

*The enclosed financials reflect Fiscal Year 2006 from July 1, 2005 - June 30, 2006.
 Community Research Initiative of New England thanks all our supporters. Without you, we could not continue our work to find safer
COMMUNITY RESEARCH INITIATIVE OF NEW ENGLAND, INC. and more effective HIV treatments and ensure access to them. The following made contributions to CRI during Fiscal Year 2006
(July 1, 2005 - June 30, 2006):
$1500+ Michael Cunningham & Ken Corbett Jose J. Medina Roslyn K. Carkhuff in memory of Anne Morris, MD
Ronald E. Akie James & Cheryl Curtin in memory of Robert Colón & Orlando Falcón John W. Carmilia & J. H. Miner
S TAT E M E N T O F F I N A N C I A L P O S I T I O N David Aronstein Michele & Donald D'Amour Elisabeth Medvedow & Clifford Cohen William D. Cattey
Robert R. Beck in memory of Anne Morris, MD in honor of Joel Goldstein & Reed Goodman Susan Cervantes
J U N E 30, 2006 ( W I T H C O M PA R AT I V E T O TA L S FOR 2005) Ronald Chapman & Crane McCune Doug Danzey Rev. John B. & Wright P. Morris Shirley Cloutier in memory of Anne Morris, MD
Earl & Helen Colson in honor of Amy Colson, MD Pat Daoust in memory of Anne Morris, MD in memory of Anne Morris, MD Patricia Cocozza in memory of Anne Morris, MD
Jonathan Crutchley Colgate W. Darden IV Laurence Moser Brenda Cole
Lynn Deitzer Philip N. Dearborn Steven M Moskowitz Agustina Serrano Colón in memory of Robert Colón
2006 2005 John W. Devlin Janet Deegan & Constance Cervone Rhorian J. Moss Jacquelyn K. & Allen S. Cressy
ASSETS Michael R. Eisenson Joanne Delaney Paul Murphy in memory of Anne Morris, MD
Jonathan Goode & Cary Raymond Raymond F. Delano Shirin & Gerald Nash, MD John S. Crocker, Jr. & Agatha S. Littlefield
William J. J. Gordon Family Foundation Bill Dellea in memory of Anne Morris, MD in memory of Anne Morris, MD
in memory of William J.J. Gordon Thomas Desanto Frank Navarro & Julio Hernandez Patricia Crosthwait
Current Assets Lyle & Lisbeth Hall in memory of Peter Clark Dana DeSimone Paul & Janet Nicholas Luz Cruz in memory of Robert Colón
Harbor to the Bay Ride Terry Dewis & Andy Casas Monica Nishi James Curtis
Cash and cash equivalents $ 36,944 $ 130,165 Lawrence R. Hyer Richard Dickinson Numeric, Inc. in memory of Anne Morris, MD Anne-Marie Desroches, RN
Gilbert Kahn & John Noffo Kahn Kenneth D. Dietz Robert O'Malley Gretchen M. Dock
Contract receivables 1,933,802 1,500,681 Julie Marston Margaret A. Drain Richard F. O'Mara Frank Dunn
Ellen Morris McCann & Peter McCann Eric E. Dray Rene Paridis in memory of Anne Morris, MD Kia R. Earp
Prepaid expenses 656,311 658,833 in memory of Anne Morris, MD Paul Dructor Graydon Parrish Evangelos Efstathiou
Michael W. McGuill & Jonathan Scott Dennis Duffy David Passer & Marc Maxwell Michele J. Feinstein in memory of Anne Morris, MD
Total current assets 2,627,057 2,289,679 The estate of Anne B. Morris, MD Dennis Edwards & Mark Steinberg Paul Samuel Pegram in memory of Anne Morris, MD Aili & Austin Flint
Frank A. Ribaudo & Joe Posa in honor of Tim Reed Tom & Bethany Edwards Alvaro E. Pertuz Shelia H. Forester
Albert Eldridge & Michael Wohlfeiler, MD Glenn E. Petersen Jenny Foster
Property and Equipment (net) $1000-$1499 in honor of Gustavo Basalo Rob Phelps Andrew M. Fullem in honor of Michael McGuill
69,399 96,547 Jay Anderson Charles & Nancy C. Eliot in memory of David Eliot Jamie Pierce & Rick Cresswell Andi Genser
Dr. Jane Boyd & Dr. Peter V. Koeppe Andy & Paul Epstein Barry M. Pike Eileen Goldman in honor of Paul Gropien
in memory of Anne Morris, MD Joan Epstein & Burt Franzman Lisa A. Pintchman Rogers & Jay Rogers Eileen Goldman in honor of Saul Palder
Total Assets $ 2,696,456 $ 2,386,226 Barbara and Vincent Daidone in honor of Jon Goode & Cary Raymond Stephen R. Powell Richard Goldstein, MD
Bernard Dreiblatt Peter J. Epstein Harold I. & Frances G. Pratt Dr. I. Luis Gomez in memory of Anne Morris, MD
Brian Farley & Ron Alose Luis E. Escobar in memory of Anne Morris, MD in memory of Anne Morris, MD Mark Gonthier
Bill Hahne & Jim Baxter Robert A. Familetti John Priovolos & Ingrid Reyes Nicole Goode
LIABILITIES AND NET ASSETS Tim Harrington & Juan Urtubey William Farmer in honor of many friends Allan Randolph Coley Gray
Robert B. Kelley & Glenn Daidone Anthony R. Felice Carol A. Rauch in memory of Anne Morris, MD Elaine J. & Edward Groipen in honor of David Morris
William Jacob Murray, III, DMD Ricardo Ferrer Barbara Reinhold in memory of Sandy Lovejoy Anne Habel
Gary Reinhardt Alvan E. Fisher, MD in memory of Anne Morris, MD Linda Richards Timothy Higgins
Current Liabilities Robert John Risse Eric Fix Edwin Rivera & Jonathan R. Hettinger Joan Howley in memory of Anne Morris, MD
Paul A. Ross Abby Flam Dan Robertson James R. & Judi Kotanchik
Accounts payable $ 2,211 $ 4,703 Peter Tenggren Carlos Flores, MD in memory of Anne Morris, MD Douglas W. Robertson James A. Kotusky in memory of Anne Morris, MD
Ralph S. Troupe Michael Foley in memory of Anne Morris, MD Joel & Beatrice Krensky in honor of Elaine Matisoff
Accrued expenses 1,155,352 1,162,398 Donald E. Vaughan & Lee Ridgway Sonya Franklin Larry Rosenberg Peter Kronenberg
Alan E. Freedman in honor of Lenore Jackson-Pope Paul Rotell John S. Kyper
Accrued salary and vacation compensation 181,556 177,892 $500-$999 Jonna I. Gaberman & Bruce Wintman Dennis Roy Kevin Labonville
Service fee advances Anonymous in memory of Anne Morris, MD James Samson Alice L. Lawrence in memory of Anne Morris, MD
249,062 4,194 Brian Back Elizabeth & Seth Gadinsky Rodney Schimko Laurie Leibowitz
Capital lease obligation - current portion Sandy Berris Sarah C. & Lloyd M. Garrison Carol Schraft Sandra E. & Michael J. Lemanski, MD
6,673 6,673 Bruce & Kerry Claflin in memory of Anne Morris, MD Eric Schulze in memory of Anne Morris, MD
Total current liabilities 1,594,854 1,355,860 Club Café Joel Goldstein & Reed Goodman Richard & Margaret Schwartz Mike Lew
Dixie-Lee Esseltine, MD Ronald H. Goldstein in memory of Richard Schwartz Karen L. Lurie in honor of Elaine Matisoff
Carlo Gambino Walter A. Goldstein & Toni Walzer Steve Schwartzberg in honor of Craig Wells Robert Maietta, MD
Sharon Gray Richard Gonzalez Bradley Seeman John C. Makiej in memory of Anne Morris, MD
Long Term Liabilities - Capital lease obligation 21,807 28,480 Seth Grosshandler & Kim Wainwright Paul Goulet Maria R. Serrano MassMutual
Roger M. Hanzes Edward P. Griffey & Bernard J. Pont in memory of Robert Colón & Orlando Falcón Ismael & Marcelina Medina
William Jorgenson & Brian Galloway Paul O. Groipen Alexander G. Sheble-Hall in memory of Robert Colón & Orlando Falcón
Eric E. Lochner Anthony Guerriero & Ricardo Mello William J. Sherald, Jr. & Jeffrey I. Lavine Lawrence G. Millhofer, MD
Net Assets 1,079,795 1,001,886 John B. Morris, Jr. in memory of Anne Morris, MD Robert S. Haas Cynthia J. Shilkret, PhD in memory of Anne Morris, MD David Morris
Mike O'Hagan & Mark Gallant Kenneth Hahn & Hugh M. Bowen Julie M. Sieben Alice J. Mullowney
Marie O'Shea Kathryn Hall Julie Simms & Joshua R. Levy C. Gwyneth Munn in memory of Anne Morris, MD
Richard J. Owen Peter J. Halpern Kathleen Singleton in memory of Anne Morris, MD Ellen Neuhaus in memory of Anne Morris, MD
Total Liabilities and Net Assets $ 2,696,456 $ 2,386,226 Pioneer Valley Nephrology Kendall Hamersly Ronald L. Skates David O'Connor
in memory of Anne Morris, MD Eric Hasper & Mark Murphy Daniel J. Skiest, MD in memory of Anne Morris, MD Elizabeth & George O'Hagan
Hanson S. Reynolds Nancy & Frank Haydu Jonathan Slater, MD in memory of Anne Morris, MD Maryalice O'Hearn-Yafrate
Steve Roberge & Samuel V. Desimone Hewlett Foundation Andrew Smith Samuel A. & Elizabeth S. Otis
South Congregational Church Deborah Hoadley in memory of Anne Morris, MD Craig Smith & Rafael Rodriguez Charles & Mildred Pintchman
S TAT E M E N T O F A C T I V I T I E S Lee Teitel
Ann Webster
Daniel J. Hochman & Douglas DiMartile John B. Smith, Jr. in honor of Lisa Pintchman Rogers
Jeremy Holman Richard Smith Robert & Shirley Pratt in memory of John Anton
F O R T H E Y E A R E N D I N G J U N E 30, 2006 ( W I T H C O M PA R AT I V E T O TA L S F O R 2005) Kathleen Whalen Sarah B. Holmes in memory of Anne Morris, MD Kathleen B. & Robert S. Sobolewski Erline Provost in memory of Anne Morris, MD
Yin Hsu Lorna Isabel Solis in honor of Larry Hyer Janice L. Quiram
$100-$499 Rev. Olivia H. Huntington Elizabeth Sommers Neil B. & Amy Raymond
2006 2005 Anonymous in memory of Anne Morris, MD Michael P. Sorenson Elaine Rosen
Jacques Abatto & David Goldman Sheila Hussey Scott St. Cyr Dr. Henry Rosenberg & Dr. Katherine M. Hicks
Marian Abraham Lenore Jackson-Pope Michael Stake in memory of Anne Morris, MD
Michael Agrifolio Richard & Ilene B. Jacobs Todd Stevenson David Ryder
Support and Revenue AIDS Action Committee of MA Jay Jakubouski Andrew Stewart Mary Jo Safford in memory of Anne Morris, MD
in memory of Anne Morris, MD James P. Jennings Susan Stinson Myrna Schulte
Contributions $ 334,796 $ 400,108 Robert & Susan Akie in honor of Ron Akie Glenn Johanson Edward E. Straub Rabbi Herbert N. Schwartz
Theodore F. Alcarez, III Mary Ann Jones Chris Sullivan in memory of Anne Morris, MD
Contract revenue* 17,081,015 21,152,894 Richard Alther Salome Juethner in memory of Karsten Kley Charles R. Tash Walter & Nancy Sheble
Jon & Matt Andersen-Miller Audrey & Jack Kadis Laura Teodosio Maureen Skipper in memory of Anne Morris, MD
Interest 28,056 8,631 Jon Appelbaum, MD Allan J. Kamlot Doreen Thompson & Richie Baron Beverly Smith in memory of Anne Morris, MD
Jack M. Armitage Margaret Kanouse in memory of Louise Zanar Barbara Torrey Paul W. Smith & Timothy W. Leahy
Other 60,382 2,533 Russell Atlas in honor of Leo Radoff Nish Kasturiratne Thomas L. Tostengard John P. Spagnoletti in honor of Mark Douville
Steven Avruch John A. Keith & Terry D. Lighte Dean Trantalis Steve Steckel, PharmD
Guy Backlund Robert & Eleanor P. Kelley William Trinkle Lin Stoia in memory of Anne Morris, MD
Total Support and Revenue 21,564,166 Mary M. Ball in memory of Anne Morris, MD Eugene F. Kelly in honor of Ken Lima & Mark Sacco Alexandra Tyszka & Diane M. Hudson Leon Sussman & Jonathan W. Green
17,504,249 Richard Bankhead in honor of Elaine Groipen Robert P. Kelly Paul Viviano William Sweet
Joel & Phyllis Baron in honor of Ron Akie Richard Kestler & James Bracciale Brad Walker Ellen Tedaldi in memory of Anne Morris, MD
Andrew F. Barowsky Julia I. Kyle in memory of Anne Morris, MD Alan Wartenberg, MD Joann R. Tomlinson in memory of Anne Morris, MD
Expenses Walter Batt Chris La Pierre Henry Weinberger, Pam McCormick, Barbara Turk, Marcia & Ronald Turner in memory of Anne Morris, MD
Yvette & Daniel Belmont in memory of Tom Romano Jim LaBrie & Nancey Kinlin in honor of Cal Cohen Verizon Foundation
HIV Drug Assistance Program* 15,239,456 19,259,209 David P. Berarducci Mark A. Landin Craig Wells Donald Warren
Jane Bermont Melvyn J. Lapes, MD in memory of Anne Morris, MD Alan J. Wild & Robert Walsh Stephen R. Watson in memory of Alan Matheaus
Community–based HIV research 1,298,259 1,579,353 Eugene & Flyura Bernstein William J. Lawrence in memory of Anne Morris, MD Patterson Wolfe in memory of Anne Morris, MD Michael Weintraub & Diane Rosen
Alfred B. Bigelow in memory of Anne Morris, MD Ellen M. Lazarus in memory of Anne Morris, MD Thomas Wyatt Marie Whelan
Education and outreach 268,729 328,613 Andrew Bigelow & Brian Lighty John V. Lesko Richard & Stephanie Yirikian Sarah W. & Joseph F. Whinery
Kris E. Bodendorf & Luann Rose M. Catherine Lewis & Angela Bonazinga James G. Young in memory of Anne Morris, MD
Total program services 16,806,444 21,167,175 in memory of Anne Morris, MD Jim Link Stephen H. Zinner, MD Irene R. Whitman in memory of Alan Matheaus
Tom Boland & Jim Farley Mark H. Lippolt & Scott MacDonald Maurice & Emily Zylber Lisa M. Wilgus in memory of Anne Morris, MD
Carol A. Bova in memory of Anne Morris, MD Patricia L. Longworth in memory of Anne Morris, MD Kathleen Wilson
Stephen M. Brady & Rafael E. Jaen Matt MacDonald $<100
General and administrative 481,699 419,090 Jason Bromberg Mark E. Maczka in memory of Anne Morris, MD James Aisner in memory of Nick Houpis Businesses, Corporations and Foundations
Fundraising Kevin Brousseau Christopher & Jo Anne Magee Joseph Allan in memory of Anne Morris, MD Community Research Initiative of New England gratefully
138,197 143,804 David S. Brown Ann Maguire & Harriet Gordon Joann E. Andrews in memory of Anne Morris, MD acknowledges the generous support of many businesses,
Total supporting services 619,896 562,894 Wayne R. Brown in memory of Anne Morris, MD George Mair Angela Dos Santos Anselmo corporations and foundations. Thanks to the following
Michael R. Burke in memory of Nick Houpis Carla Marcinowski Stuart Armstrong, II organizations for their contributions of $1000 or more
Sarah Callahan in honor of the CRI Bike Team Linda J. Markarian Shari Ascher during Fiscal Year 2006 (July 1, 2005-June 30, 2006):
Mary Ellen Cantabene James K. Marko & Jacob Smith Yang Mark Baker
Total Expenses 17,426,340 21,730,069 David Caporini Tom Martin Andrew H. Balder Abbott Virology
Robert Caro Elaine Matisoff Baycare Health Partners Boehringer Ingelheim Pharmaceuticals, Inc.
Bob Carr & Stephen Rivais Guy N. Matsuda & Philip Allessio in memory of Anne Morris, MD Boston Gay Rights Fund
William M. Carson in memory of Anne Morris, MD Anne M. & Jacob B. Berlin Bristol-Myers Squibb
Change in Net Assets 77,909 (165,903) Daryl J. Caudry Kenneth F. Mayer, MD in memory of Anne Morris, MD in memory of Anne Morris, MD Community Health Charities
Senator & Mrs. Lincoln D. Chafee Dennis E. McAvoy & Bruce Poduska Bartlett Berlin in memory of Anne Morris, MD Irene E. & George A. Davis Foundation
Jerry S. Chasen & Mark Kirby Crane McCune in memory of Bob LaTraverse Leelo Bertram Gilead Sciences
Choice Foundation in memory of Anne Morris, MD Michael McGinnity Carolyn P. Bess in honor of Craig Wells Knowledge Solutions LLC
Net Assets - Beginning of Year 1,001,886 1,167,789 Mark Christofi McGovern & Bajaj Allergy Associates, P.C. Robert G. & Karen J. Bourgeault M.A.C AIDS Fund
Anjelica Cohn in memory of Anne Morris, MD in memory of Anne Morris, MD Miami Home
Kevin Condon Elizabeth H. McGrail Charles E. & Sarah P. Breed Pride Mortgage
Michael S. Cook John McGuirk in memory of Anne Morris, MD
Net Assets - End of Year $ 1,079,795 $ 1,001,886 Patrice Cormier & Joslin Stewart Eileen O'Brien Mead Joyce M. Brousseau in memory of Anne Morris, MD
Racepoint Group Inc.
Roche
Joseph P. Cozzolino in memory of Anne Morris, MD Dermot Meagher Kim Bullano in memory of Anne Morris, MD Sculptra TM
Marc Croteau Padric Meagher John Campbell Tibotec Therapeutics
Wainwright Bank
* CRI received $14,318,588 (FY'06) and $17,640,218 (FY'05) to operate the HIV Drug Assistance Program (HDAP)
with direct pass-through funding to purchase medications and healthcare insurance for eligible clients.
Every effort has been made to ensure the accuracy of this list. We apologize for any errors and ask that you call our Development Office at 617.778.5454, ext. 347, or email corrections to sgray@crine.org.
* For CRI’s complete audited financial report, please contact us at info@crine.org